


PHARMACEUTICAL 2022

MACROGENICS INC Rank 265 of 466







PHARMACEUTICAL 2022

MACROGENICS INC Rank 265 of 466



The relative strengths and weaknesses of MACROGENICS INC are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of MACROGENICS INC compared to the market average is the variable Other Liabilities, increasing the Economic Capital Ratio by 28% points. The greatest weakness of MACROGENICS INC is the variable Research and Development, reducing the Economic Capital Ratio by 55% points.

The company's Economic Capital Ratio, given in the ranking table, is 97%, being 20% points above the market average of 78%.

Input Variable	Value in 1000 USD
Assets, Current	279,560
Cost of Goods Sold	2,651
Intangible Assets	0
Liabilities, Current	74,578
Liabilities, Non-Current	21,049
Other Assets	18,009
Other Compr. Net Income	-54
Other Expenses	0
Other Liabilities	0
Other Net Income	680
Other Revenues	77,447
Property and Equipment	37,676
Research and Development	214,577
Selling, General and Administrative Expense	63,014

Output Variable	Value in 1000 USD
Assets	335,245
Liabilities	95,627
Expenses	280,242
Revenues	77,447
Stockholders Equity	239,618
Net Income	-202,115
Comprehensive Net Income	-202,142
Economic Capital Ratio	97%

